Henry Viola-Heir

A personal update

Following a change in my personal circumstances, I am stepping away from publishing investment-related media activity. As a result there will be no new articles or updates on Capital Ledger, and I am no longer able to participate in the Twin Petes Investing podcast. The site will remain live. Capital Ledger has been a part […]

A personal update Read More »

Judges Scientific: When Great Businesses Have Bad Years

For much of the past two decades, Judges Scientific (LSE:JDG) has been one of the UK’s outstanding compounders with a “buy and build” strategy: acquire high-quality scientific instrument businesses, give talented management teams the freedom to run them, allocate capital carefully, and allow time to compound the returns. The results have been fantastic. Revenue, earnings

Judges Scientific: When Great Businesses Have Bad Years Read More »

What a Design Win is Worth

“Not every order begins with a purchase. Some begin with a decision.” One phrase appears repeatedly throughout the engineering and technology sectors. “The company has secured several important design wins”. It sounds encouraging and markets often react positively. Management teams highlight the announcements, and investors often add another point to the investment case, but relatively

What a Design Win is Worth Read More »

Concurrent Technologies: Becoming a Durable Compounder?

There are some businesses I own because their appeal lies in my understanding of their products. Concurrent Technologies (LSE:CNC) isn’t one of them. The company designs and manufactures high-performance embedded computing systems for applications in scenarios where failure is an unacceptable event. Think defence, aerospace, and industrial applications; environments where reliability is highly prized. Concurrent

Concurrent Technologies: Becoming a Durable Compounder? Read More »

2026 – Half Year Review

The first half of 2026 was less about discovering new investment opportunities and more about developing my approach to the stewardship of capital. I exited several long-term positions as my conviction deteriorated, reallocated capital towards higher-quality compounders and introduced a more deliberate framework for portfolio construction. Some of these decisions were prompted by changes in

2026 – Half Year Review Read More »

It’s The Most Vacuous Time Of The Year: Why Most Annual Reviews Tell You Almost Nothing of Value

Every January, investors conduct the same familiar exercise – an exercise which is rapidly approach again. Twelve months of market activity are compressed into a neat sequence of charts and percentages, then we draw conclusions with an air of finality that the underlying evidence does not support. The problem is not that annual reviews exist.

It’s The Most Vacuous Time Of The Year: Why Most Annual Reviews Tell You Almost Nothing of Value Read More »